{
  "compound": "CBD (dose-escalation)",
  "condition": "PARKINSONS",
  "effect_size": "Safety profile established",
  "study_type": "RCT",
  "source": "NORML:PD_RCT_004",
  "participants": "6 PD patients with treatment-resistant symptoms",
  "year": 2009,
  "notes": "THC:CBD Oromucosal Spray for PD Pain and Non-Motor Symptoms",
  "confidence": "medium",
  "abstract": "No worsening of motor symptoms at any dose; Psychotic symptoms (hallucinations) did not worsen; Anxiety reduced"
}